These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6686565)

  • 21. Is there any need for a TAFI(a) inhibitor as thrombolytic drug?
    Vercauteren E; Gils A
    Thromb Res; 2012 Oct; 130(4):574-5. PubMed ID: 22840781
    [No Abstract]   [Full Text] [Related]  

  • 22. [Lysis of fresh experimental thrombi under the action of a secondary adrenaline-heparin-fibrinogen complex].
    Liapina LA; Zhitnikova ES; Kudriashov BA
    Farmakol Toksikol; 1978; 41(1):82-5. PubMed ID: 624394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fibrinolytic and thrombolytic properties of a plasminogen activator isolated from the culture broth of calf kidney cells].
    Egorov BB; Andreenko GV; Liaginskiĭ AV; Stelingovskií KV; Podorol'skaia LV
    Farmakol Toksikol; 1983; 46(4):54-6. PubMed ID: 6684592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined use of terrilytin, sodium salicylate and heparin for the purpose of regulating hemostasis].
    Mamedov IaD; Reĭsh AV
    Probl Gematol Pereliv Krovi; 1981 May; 26(5):52-5. PubMed ID: 6166936
    [No Abstract]   [Full Text] [Related]  

  • 25. Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity.
    Drozdov AS; Vinogradov VV; Dudanov IP; Vinogradov VV
    Sci Rep; 2016 Jun; 6():28119. PubMed ID: 27321930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Trichothecene inactivation by proteolytic enzymes from Trichothecium roseum Lk ex Fr].
    Maksimova RA; Pokh LI; Silaev AB
    Antibiotiki; 1975; 20(12):1081-5. PubMed ID: 1225182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advancement on thrombolytic characteristic, function and clinical application of different fibrinolytic enzymes].
    Sun Y; Wang W; Li C
    Zhongguo Zhong Yao Za Zhi; 2010 Mar; 35(6):794-8. PubMed ID: 20545212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombolytic therapy. I. Introduction and principles of therapy. Indications. Contraindications. Schematics of the treatment].
    Sterkowicz S
    Przegl Lek; 1969; 25(8):565-8. PubMed ID: 4897431
    [No Abstract]   [Full Text] [Related]  

  • 29. [The marine bacterium Alteromonas piscicida--a producer of enzymes with thrombolytic action].
    Demina NS; Veslopolova EF; Gaenko GP
    Izv Akad Nauk SSSR Biol; 1990; (3):415-9. PubMed ID: 2205639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel human microplasmin fold: new perspective to thrombosis treatment.
    Joison AN; Gallo FS
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):236-9. PubMed ID: 21245749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New strategies in the development of thrombolytic agents.
    Lijnen HR; Collen D
    Curr Stud Hematol Blood Transfus; 1991; (58):69-72. PubMed ID: 1954777
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
    Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Heparin-urea complex and its biological properties].
    Liapina LA; Kudriashov BA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1975; (10):46-9. PubMed ID: 1203401
    [No Abstract]   [Full Text] [Related]  

  • 34. [Development of research into the physiology and pathophysiology of the fibrinolysis system].
    Andreenko GV
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (10):5-19. PubMed ID: 2933082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thrombolytic effect of tricholysine in experimental thrombosis].
    Gavrilov OK; Murashova NS; Sirotenko AV; Subbotina LA; Kozlova MA
    Gematol Transfuziol; 1983 Jul; 28(7):37-41. PubMed ID: 6352393
    [No Abstract]   [Full Text] [Related]  

  • 36. Theoretical and practical aspects of thrombolytic therapy.
    Hirsh J
    Angiology; 1977 Jan; 28(1):1-6. PubMed ID: 326096
    [No Abstract]   [Full Text] [Related]  

  • 37. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current developments in thrombolytic therapy.
    Sherry S
    Thromb Diath Haemorrh Suppl; 1973; 56():201-10. PubMed ID: 4617330
    [No Abstract]   [Full Text] [Related]  

  • 39. Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo.
    Hashimoto M; Onobayashi Y; Oiwa K; Giddings JC; Yamamoto J
    Thromb Res; 2002 Apr; 106(2):165-8. PubMed ID: 12182917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.